Development Pipeline
From clinical-stage pharmaceutical assets to innovative medical devices — our pipeline addresses critical unmet needs across dermatology, ophthalmology, and nephrology.
Commercially Mature Assets
Our flagship programs are either in advanced clinical development or already generating commercial revenue through registered consumer products.
ErpeCream®
Phase IIb in progressRecurrent genital HSV-2
First-in-class topical immunomodulator. Oil-in-water nanoemulsion with 5 synergistic botanical actives. 97% efficacy in 96h (Phase II). Head-to-head vs acyclovir study ongoing.
Seeking co-development partner or licensing agreement
ErpeLips™
Commercialization phaseCold Sores (HSV-1)
Pocket-size solution for cold sores. 70% proven efficacy. Results in 24 hours. 100% natural patented formula. Compact 3ml format.
Seeking distribution partners globally
Programs in Development
Early-stage programs with significant market potential, seeking development partners and investment.
ACRO-EYE™
Galenic use → Phase IIITacrolimus ophthalmic for Keratoconjunctivitis Sicca (KCS)
No direct equivalent in galenic ophthalmic market. 10–30x lower dose than systemic. Only alcohol-free Tacrolimus eye drops available.
Autoimmune dry eye conditions affect millions globally with limited effective treatment options.
Advanced galenic formulation providing targeted immunomodulation with minimal systemic exposure.
Galenic use established. Phase III pathway being formalized.
Co-development or licensing
Easy-Dialysis™
Prototype → CE MarkingPortable Hemodialysis (suitcase format)
Continuous-flow portable hemodialysis device. Proportional blending control with microelectronics safety systems.
Global dialysis market >€90B annually. Patients face significant quality of life limitations with current dialysis options.
Portable continuous hemodialysis system enabling patient mobility and improved quality of life.
Prototype completed. CE Marking pathway in progress.
Investment required: €3–4M for clinical validation and CE Marking
Partner With Us
We are actively seeking strategic partners for clinical development, commercialization, and global distribution.